InvestorsObserver is giving Recursion Pharmaceuticals Inc (RXRX) an Analyst Rating Rank of 18, meaning RXRX is ranked higher by analysts than 18% of stocks. The average price target for RXRX is $13 and analyst’s rate the stock as a Buy.
Wall Street analysts are rating RXRX a Buy today. Find out what this means to you and get the rest of the rankings on RXRX!
Though analyst projections should not be your only resource when determining your position on a stock, it can be a very useful tool. Analysts follow sectors/industries in-depth and tend to know how local and global conditions tend to affect demand and prices. Many analysts even participate in conference calls where they can get information to better make sense of the numbers.
InvestorsObserver averages the ratings provided by analysts and then ranks their score as a percent against the market. This allows you to compare stocks in a more comprehensive fashion than with the typical buy/sell/hold ranking.
What's Happening With Recursion Pharmaceuticals Inc Stock Today?
Recursion Pharmaceuticals Inc (RXRX) stock is trading at $10.47 as of 12:21 PM on Monday, Mar 25, a decline of -$0.02, or -0.19% from the previous closing price of $10.49. The stock has traded between $10.42 and $10.91 so far today. Volume today is light. So far 1,662,468 shares have traded compared to average volume of 8,843,824 shares.
Click Here to get the full Stock Report for Recursion Pharmaceuticals Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
